Importantly, our results indicated that the combination treatment of Roblitinib (FGFR4 inhibitor) and CPI-169 (EZH2 inhibitor) synergistically induced HCC cell apoptosis in vitro and suppressed the zebrafish/mouse HCC xenografts and zebrafish HCC primary tumors development in vivo. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.